Modulation of cancer cell survival pathways using multivalent liposomal therapeutic antibody constructs

Molecular Cancer Therapeutics

Volumn 6, Issue 3, 2007, Pages 844-855

  Chiu, Gigi N C ^a,b   Edwards, Lincoln A ^a   Kapanen, Anita I ^a   Malinen, Melina M ^a   Dragowska, Wieslawa H ^a   Warburton, Corinna ^a   Chikh, Ghania G ^a   Fang, Karen Y Y ^a   Tan, Sophia ^a   Sy, Jonathan ^a   Tucker, Catherine ^a   Waterhouse, Dawn N ^a   Klasa, Richard ^a   Bally, Marcel B ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; LIPOSOME; PROTEIN KINASE B; RITUXIMAB; RITUXIMAB LIPID COMPLEX; TRANSCRIPTION FACTOR RELA; TRASTUZUMAB; TRASTUZUMAB LIPID COMPLEX; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BREAST TUMOR; CANCER CELL; CANCER IMMUNOTHERAPY; CELL SURVIVAL; CELL VIABILITY; CLUSTER ANALYSIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG MEGADOSE; DRUG POTENCY; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; IMMUNOMODULATION; LIPOSOMAL DELIVERY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIGENS, CD20; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL SURVIVAL; DNA-BINDING PROTEINS; DOWN-REGULATION; FEMALE; FLOW CYTOMETRY; GENES, ERBB-2; HUMANS; LIPOSOMES; MICE; MICE, KNOCKOUT; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR RELA;

EID: 34147130831     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-06-0159     Document Type: Article

References (54)

1. Carter P. Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer 2001;1:118-29.
2. Presta LG, Shields RL, Namenuk AK, et al. Engineering therapeutic antibodies for improved function. Biochem Soc Trans 2002;30: 487-90.
3. Groner B, Hartmann C, Wels W. Therapeutic antibodies. Curr Mol Med 2004;4:539-47.
4. Zhang N, Khawli LA, Hu P, Epstein AL. Generation of rituximab polymer may cause hyper-cross-linking-induced apoptosis in non-Hodgkin's lymphomas. Clin Cancer Res 2005;11:5971-80.
5. Nagy P, Jenei A, Damjanovich S, et al. Complexity of signal transduction mediated by ErbB2: clues to the potential of receptor-targeted cancer therapy. Pathol Oncol Res 1999;5:255-71.
6. Deans JP, Li H, Polyak MJ. CD20-mediated apoptosis: signalling through lipid rafts. Immunology 2002;107:176-82.
7. Todorovska A, Roovers RC, Dolezal O, et al. Design and application of diabodies, triabodies, and tetrabodies for cancer targeting. J Immunol Methods 2001;248:47-66.
8. Shan D, Ledbetter JA, Press OW. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 1998;91: 1644-52.
9. Ghetie MA, Bright H, Vitetta ES. Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin. Blood 2001;97:1392-8.
10. Hommelgaard AM, Lerdrup M, van Deurs B. Association with membrane protrusions makes ErbB2 an internalization-resistant receptor. Mol Biol Cell 2004;15:1557-67.
11. Miller K, Meng G, Liu J, et al. Design, construction, and in vitro analyses of multivalent antibodies. J Immunol 2003;170:4854-61.
12. Wittel UA, Jain M, Goel A, et al. The in vivo characteristics of genetically engineered divalent and tetravalent single-chain antibody constructs. Nucl Med Biol 2005;32:157-64.
13. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 2005;4:145-60.
14. Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science 2004;303:1818-22.
15. Allen TM. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 2002;2:750-63.
16. Maruyama K. PEG-immunoliposomes. Biosci Rep 2002;22:251-66.
17. Sapra P, Allen TM. Ligand-targeted liposomal anticancer drugs. Prog Lipid Res 2003;42:439-62.
18. Park JW, Benz CC, Martin FJ. Future directions of liposome- and immunoliposome-based cancer therapeutics. Semin Oncol 2004;31: 196-205.
19. Park JW, Hong K, Carter P, et al. Development of anti-p185HER2 immunoliposomes for cancer therapy. Proc Natl Acad Sci U S A 1995;92: 1327-31.
20. Woodle MC, Lasic DD. Sterically stabilized liposomes. Biochim Biophys Acta 1992;1113:171-99.
21. Allen TM, Brandeis E, Hansen CB, et al. A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells. Biochim Biophys Acta 1995;1237: 99-108.
22. Maruyama K. Long-circulating immunoliposome targeting in animal models. J Liposome Res 1997;7:363-89.
23. Weiner LM, Carter P. Tunable antibodies. Nat Biotechnol 2005;23: 556-7.
24. Baselga J. Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials. Oncology 2001;61:14-21.
25. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med 2002;346:235-42.
26. Hansen CB, Kao GY, Moase EH, et al. Attachment of antibodies to sterically stabilized liposomes: evaluation, comparison, and optimization of coupling procedures. Biochim Biophys Acta 1995;1239:133-44.
27. Chiu GN, Bally MB, Mayer LD. Targeting of antibody conjugated, phosphatidylserine-containing liposomes to vascular cell adhesion molecule 1 for controlled thrombogenesis. Biochim Biophys Acta 2003;1613: 115-21.
28. Warburton C, Dragowska WH, Gelmon K, et al. Treatment of HER-2/neu overexpressing breast cancer xenograft models with trastuzumab (Herceptin) and gefitinib (ZD1839): drug combination effects on tumor growth, HER-2/neu and epidermal growth factor receptor expression, and viable hypoxic cell fraction. Clin Cancer Res 2004;10:2512-24.
29. Mayer LD, Hope MJ, Cullis PR. Vesicles of variable sizes produced by a rapid extrusion procedure. Biochim Biophys Acta 1986;858:161-8.
30. Leserman LD, Barbet J, Kourilsky F, et al. Targeting to cells of fluorescent liposomes covalently coupled with monoclonal antibody or protein A. Nature 1980;288:602-4.
31. Hope MJ, Bally MB, Webb G, et al. Production of large unilamellar vesicles by a rapid extrusion procedure. Characterization of size distribution, trapped volume and ability to maintain a membrane potential. Biochim Biophys Acta 1985;812:55-65.
32. Lu Y, Zi X, Zhao Y, et al. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 2001;93: 1852-7.
33. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2002;2:489-501.
34. Knuefermann C, Lu Y, Liu B, et al. HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene 2003;22:3205-12.
35. Clark AS, West K, Streicher S, et al. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther 2002;1:707-17.
36. Ozes ON, Mayo LD, Gustin JA, et al. NF-κB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 1999;401: 82-5.
37. Romashkova JA, Makarov SS. NF-κB is a target of AKT in antiapoptotic PDGF signalling. Nature 1999;401:86-90.
38. Pommier Y, Sordet O, Antony S, et al. Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene 2004;23:2934-49.
39. Chikh G, Kapanen AI, Turner C, et al. A multivalent formulation of rituximab exhibits significant activity against mantle cell lymphoma cell lines. In: Annual Meeting of the American Association of Immunologists, Boston, MA, U.S.A., May 12-16 2006.
40. Li H, Ayer LM, Polyak MJ, et al. The CD20 calcium channel is localized to microvilli and constitutively associated with membrane rafts: antibody binding increases the affinity of the association through an epitope-dependent cross-linking-independent mechanism. J Biol Chem 2004;279:19893-901.
41. Sheikh MS, Garcia M, Pujol P, et al. Why are estrogen-receptor-negative breast cancers more aggressive than the estrogen-receptor-positive breast cancers? Invasion Metastasis 1994;14:329-36.
42. Dragowska WH, Warburton C, Yapp DT, et al. HER-2/neu overexpression increases the viable hypoxic cell population within solid tumors without causing changes in tumor vascularization. Mol Cancer Res 2004; 2:606-19.
43. Vermette P, Griesser HJ, Kambouris P, et al. Characterization of surface-immobilized layers of intact liposomes. Biomacromolecules 2004; 5:1496-502.
44. Noppl-Simson DA, Needham D. Avidin-biotin interactions at vesicles surfaces: adsorption and binding, cross-bridge formation, and lateral interactions. Biophys J 1996;70:1391-401.
45. Clynes RA, Towers TL, Presta LG, et al. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000;6: 443-6.
46. Ghetie MA, Podar EM, Ilgen A, et al. Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells. Proc Natl Acad Sci U S A 1997; 94:7509-14.
47. Pham LV, Tamayo AT, Yoshimura LC, et al. Inhibition of constitutive NF-κB activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J Immunol 2003;171:88-95.
48. Minn AJ, Rudin CM, Boise LH, et al. Expression of bcl-xL can confer a multidrug resistance phenotype. Blood 1995;86:1903-10.
49. Chen C, Edelstein LC, Gelinas C. The Rel/NF-κB family directly activates expression of the apoptosis inhibitor Bcl-x(L). Mol Cell Biol 2000; 20:2687-95.
50. Amundson SA, Myers TG, Scudiero D, et al. An informatics approach identifying markers of chemosensitivity in human cancer cell lines. Cancer Res 2000;60:6101-10.
51. Vogel CL, Tan-Chiu E. Trastuzumab plus chemotherapy: convincing survival benefit or not? J Clin Oncol 2005;23:4247-50.
52. Avivi I, Robinson S, Goldstone A. Clinical use of rituximab in haematological malignancies. Br J Cancer 2003;89:1389-94.
53. Harding JA, Engbers CM, Newman MS, et al. Immunogenicity and pharmacokinetic attributes of poly(ethylene glycol)-grafted immunoliposomes. Biochim Biophys Acta 1997;1327:181-92.
54. Lasic DD, Papahadjopoulos D, editors. Medical applications of liposomes. New York: Elsevier; 1998. p. 1-779.